Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive

Anna Wieckowska; Ariel E. Feldstein

doi:10.1055/s-0028-1091983

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2008; 28(4): 386-395
DOI: 10.1055/s-0028-1091983

Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive

Anna Wieckowska¹ , Ariel E. Feldstein² ^, ³

¹Department of Pediatric Gastroenterology, CHUQ, Quebec City, Quebec, Canada
²Department of Pediatric Gastroenterology, Cleveland Clinic, Cleveland, Ohio
³Department of Cell Biology, Cleveland Clinic, Cleveland, Ohio

Abstract

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States and many other parts of the world. Its prevalence continues to rise—currently affecting ~20 to 30% of adults and 10% of children in the United States. NAFLD represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign nonprogressive clinical course, to steatohepatitis or NASH, a more serious form of NAFLD that may progress to cirrhosis and end-stage liver disease. Although currently a combination of noninvasive clinically available laboratory and imaging tests may help in the diagnostic evaluation of a patient with suspected NAFLD, a liver biopsy remains the only reliable way to precisely diagnose NASH and establish the severity of liver injury and presence of fibrosis. It also provides important information regarding prognosis as well as response to therapeutic interventions. However, a liver biopsy is an invasive and costly procedure, which is poorly suited as a diagnostic test for a condition that may affect about one-third of the U.S. population. This review provides a concise overview of the role of liver biopsy versus noninvasive diagnostic tools for the differentiation of fatty liver from nonalcoholic steatohepatitis as well as for the determination of presence and extent of fibrosis. In particular, this review focuses on the methods currently available in daily clinical practice in hepatology and touches briefly on potential future markers under investigation.

KEYWORDS

Fatty liver - nonalcoholic steatohepatitis - liver biopsy - noninvasive diagnostic test - biomarkers

Volltext

Referenzen

REFERENCES

1 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346 1221-1231
2 Wieckowska A, Feldstein A E. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr. 2005; 17 636-641
3 Adams L A, Lymp J F, St Sauver J et al.. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129 113-121
4 Matteoni C A, Younossi Z M, Gramlich T, Boparai N, Liu Y C, McCullough A J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116 1413-1419
5 Ekstedt M, Franzen L E, Mathiesen U L et al.. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44 865-873
6 Dam-Larsen S, Franzmann M, Andersen I B et al.. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004; 53 750-755
7 Wieckowska A, McCullough A J, Feldstein A E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007; 46(2) 582-589
8 Ramesh S, Sanyal A J. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis. 2004; 24 399-413
9 Ludwig J, Viggiano T R, McGill D B, Oh B J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55 434-438
10 Yeh M M, Brunt E M. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 2007; 128 837-847
11 Brunt E M. Pathology of fatty liver disease. Mod Pathol. 2007; 20(suppl 1) S40-S48
12 Schwimmer J B, Behling C, Newbury R et al.. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005; 42 641-649
13 Kleiner D E, Brunt E M, Van Natta M et al.. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41 1313-1321
14 Brunt E M, Janney C G, Di Bisceglie A M, Neuschwander-Tetri B A, Bacon B R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94 2467-2474
15 Adams L A, Sanderson S, Lindor K D, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005; 42 132-138
16 Coton T, Matton T, Pecarrere J L, Monchy D, Debonne J M. Interobserver reproducibility of the Knodell score and the Metavir score in chronic viral hepatitis C: results of 60 liver biopsies. Gastroenterol Clin Biol. 2001; 25 915-916
17 Ong J P, Younossi Z M. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin Liver Dis. 2005; 9 617-634 vi
18 Adams L A, Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis. 2007; 11 25-35
19 Ratziu V, Bugianesi E, Dixon J et al.. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther. 2007; 26 821-830
20 Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986; 2 165-173
21 Ratziu V, Charlotte F, Heurtier A et al.. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128 1898-1906
22 Merriman R B, Ferrell L D, Patti M G et al.. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology. 2006; 44 874-880
23 Janiec D J, Jacobson E R, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg. 2005; 15 497-501
24 Younossi Z M, Gramlich T, Liu Y C et al.. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998; 11 560-565
25 Adams L A, Talwalkar J A. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006; 40 S34-S38
26 Yano E, Tagawa K, Yamaoka K, Mori M. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol. 2001; 54 945-951
27 Nomura K, Yano E, Shinozaki T, Tagawa K. Efficacy and effectiveness of liver screening program to detect fatty liver in the periodic health check-ups. J Occup Health. 2004; 46 423-428
28 Ipekci S H, Basaranoglu M, Sonsuz A. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2003; 36 371
29 Mofrad P, Contos M J, Haque M et al.. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37 1286-1292
30 Kunde S S, Lazenby A J, Clements R H, Abrams G A. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology. 2005; 42 650-656
31 Suzuki A, Lymp J, Sauver J S, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int. 2006; 26 1209-1216
32 Lindor K D, Kowdley K V, Heathcote E J et al.. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004; 39 770-778
33 Brunt E M, Neuschwander-Tetri B A, Oliver D, Wehmeier K R, Bacon B R. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol. 2004; 35 1070-1082
34 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30 1356-1362
35 Dixon J B, Bhathal P S, O'Brien P E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121 91-100
36 Palekar N A, Naus R, Larson S P, Ward J, Harrison S A. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006; 26 151-156
37 Gholam P M, Flancbaum L, Machan J T, Charney D A, Kotler D P. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007; 102 399-408
38 Poynard T, Ratziu V, Charlotte F et al.. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6 34
39 Zein C O, Edmison J, Schluchter M, Feldstein A E, Zein N N, McCullough A JA. NASH predictive index (NPI) for use in patients with nonalcoholic fatty liver disease. Hepatology. 2007; 46 747A
40 Ratziu V, Giral P, Charlotte F et al.. Liver fibrosis in overweight patients. Gastroenterology. 2000; 118 1117-1123
41 Ratziu V, Massard J, Charlotte F et al.. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6 6
42 Angulo P, Hui J M, Marchesini G et al.. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45 846-854
43 Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005; 25 779-786
44 Lydatakis H, Hager I P, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int. 2006; 26 864-871
45 Rosenberg W M, Voelker M, Thiel R et al.. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004; 127 1704-1713
46 Guha I N, Parkes J, Roderick P et al.. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008; 47 455-460
47 Mishra P, Younossi Z M. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007; 102 2716-2717
48 Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol. 2007; 189 W320-W323
49 Hamaguchi M, Kojima T, Itoh Y et al.. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007; 102 2708-2715
50 Ryan C K, Johnson L A, Germin B I, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 2002; 8 1114-1122
51 Mottin C C, Moretto M, Padoin A V et al.. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg. 2004; 14 635-637
52 Thomas E L, Hamilton G, Patel N et al.. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut. 2005; 54 122-127
53 Szczepaniak L S, Babcock E E, Schick F et al.. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol. 1999; 276 E977-E989
54 Browning J D, Szczepaniak L S, Dobbins R et al.. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40 1387-1395
55 Saadeh S, Younossi Z M, Remer E M et al.. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123 745-750
56 Castera L, Pawlotsky J M. Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C. MedGenMed. 2005; 7 39
57 Foucher J, Castera L, Bernard P H et al.. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol. 2006; 18 411-412
58 Oliveira C P, da Costa Gayotto L C, Tatai C et al.. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J Cell Mol Med. 2002; 6 399-406
59 Roskams T, Yang S Q, Koteish A et al.. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol. 2003; 163 1301-1311
60 Day C P. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002; 16 663-678
61 Wanless I R, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis. 2004; 24 99-106
62 Bonnefont-Rousselot D, Ratziu V, Giral P, Charlotte F, Beucler I, Poynard T. Blood oxidative stress markers are unreliable markers of hepatic steatosis. Aliment Pharmacol Ther. 2006; 23 91-98
63 Chalasani N, Deeg M A, Crabb D W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004; 99 1497-1502
64 Horoz M, Bolukbas C, Bolukbas F F et al.. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol. 2005; 5 35
65 Solga S F, Alkhuraishe A, Cope K et al.. Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations. Biomarkers. 2006; 11 174-183
66 Diehl A M. Nonalcoholic fatty liver disease: implications for alcoholic liver disease pathogenesis. Alcohol Clin Exp Res. 2001; 25 8S-14S
67 Diehl A M. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis. 2004; 8 619-638 x
68 Abiru S, Migita K, Maeda Y et al.. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 2006; 26 39-45
69 Feldstein A E, Werneburg N W, Canbay A et al.. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004; 40 185-194
70 Hui J M, Hodge A, Farrell G C, Kench J G, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology. 2004; 40 46-54
71 Li Z, Yang S, Lin H et al.. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003; 37 343-350
72 Xu H, Uysal K T, Becherer J D, Arner P, Hotamisligil G S. Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes. 2002; 51 1876-1883
73 Haukeland J W, Damas J K, Konopski Z et al.. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006; 44 1167-1174
74 Hui J M, Farrell G C, Kench J G, George J. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology. 2004; 39 1458-1459
75 Feldstein A E, Canbay A, Angulo P et al.. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003; 125 437-443
76 Feldstein A E, Canbay A, Guicciardi M E, Higuchi H, Bronk S F, Gores G J. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol. 2003; 39 978-983
77 Feldstein A E, Gores G J. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci. 2005; 10 3093-3099
78 Feldstein A E, Werneburg N W, Li Z, Bronk S F, Gores G J. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol. 2006; 290 G1339-G1346
79 Li Z, Berk M, McIntyre T M, Gores G J, Feldstein A E. The lysosomal-mitochondrial axis in free fatty acids induced hepatic lipotoxicity. Hepatology. 2008; 47 1495-1503
80 Wieckowska A, Zein N N, Yerian L M, Lopez A R, McCullough A J, Feldstein A E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006; 44 27-33
81 Wieckowska A, Lopez A R, Zein N N, McCullough A J, Feldstein A E. Noninvasive assessment of hepatocyte apoptosis in nonalcoholic fatty liver disease: a multi-center validation study. Gastroenterology. 2007; 132 A729
82 Day C P. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int. 2006; 26 1021-1028
83 Huang H, Shiffman M L, Cheung R C et al.. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology. 2006; 130 1679-1687

Ariel E FeldsteinM.D.

Departments of Pediatric Gastroenterology and Cell Biology, Cleveland Clinic

9500 Euclid Avenue, Cleveland, Ohio 44195

eMail: feldsta@ccf.org